Published in Onco Targets Ther on February 23, 2015
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene (2006) 5.12
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A (1997) 4.20
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13
Osteopontin: a protein with diverse functions. FASEB J (1993) 3.93
Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev (2012) 2.82
The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol (1999) 2.00
Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res (2006) 1.79
SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol (2001) 1.76
Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett (2010) 1.51
Inflammation and ovarian cancer. Cytokine (2012) 1.49
Modulation of tumor angiogenesis by stem cell factor. Cancer Res (2000) 1.46
MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol (1999) 1.44
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res (2011) 1.35
Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer (2007) 1.30
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol (2013) 1.29
Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res (2013) 1.28
Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ (1995) 1.28
Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res (2012) 1.28
Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer (2013) 1.27
Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol (2005) 1.22
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer (2011) 1.21
Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol (2007) 1.14
Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine (2012) 1.13
Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res (1994) 1.12
Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine (2012) 1.11
Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis (2008) 1.09
The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther (2005) 1.06
Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol (1999) 1.05
Calculator for ovarian carcinoma subtype prediction. Mod Pathol (2010) 1.04
Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep (2010) 1.03
Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res (2011) 1.03
SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One (2012) 1.02
SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia (2008) 1.01
Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep (2010) 1.01
Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J Mol Med (Berl) (2012) 0.98
Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochem Pharmacol (2012) 0.98
Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem (2007) 0.96
Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer (2007) 0.95
Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci (2007) 0.93
Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim Biophys Acta (2011) 0.92
Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res (2012) 0.91
Stem cell factor (SCF)-kit mediated phosphatidylinositol 3 (PI3) kinase signaling during mammalian oocyte growth and early follicular development. Front Biosci (2006) 0.91
Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol (2012) 0.86
Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine (2013) 0.86
Clinical significance of serum DKK-1 in patients with gynecological cancer. Int J Gynecol Cancer (2009) 0.86
Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis. J Ovarian Res (2013) 0.85
Human epididymal protein 4 (HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients. Eur J Gynaecol Oncol (2012) 0.85
Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. Growth Factors (2012) 0.84
Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis (2011) 0.84
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int J Gynecol Cancer (2010) 0.84
Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol (2011) 0.83
Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis. Tumour Biol (2013) 0.83
Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol (2010) 0.83
Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. Cancer Lett (2012) 0.83
Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci (2010) 0.82
Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res (2013) 0.81
Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology (2008) 0.80
Growth differentiation factor-15 as biomarker in uterine sarcomas. Int J Gynecol Cancer (2014) 0.80
[Comparison of VEGF, IL-8 and beta-FGF concentrations in the serum and ascites of patients with ovarian cancer]. Ginekol Pol (2011) 0.79
Ovarian epithelial-stromal interactions: role of interleukins 1 and 6. Obstet Gynecol Int (2011) 0.78
The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers (2009) 0.78
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol (2011) 0.77
[Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy]. Ginekol Pol (2011) 0.76
MEK1-independent activation of MAPK and MEK1-dependent activation of p70 S6 kinase by stem cell factor (SCF) in ovarian cancer cells. Biochem Biophys Res Commun (2009) 0.75
Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res (2014) 0.85
Humoral activity of cord blood-derived stem/progenitor cells: implications for stem cell-based adjuvant therapy of neurodegenerative disorders. PLoS One (2013) 0.77
Mixed chimerism and transplant tolerance are not effectively induced in C3a-deficient mice. Exp Hematol (2014) 0.75
BDNF - A key player in cardiovascular system. J Mol Cell Cardiol (2017) 0.75
The influence of BDNF on human umbilical cord blood stem/progenitor cells: implications for stem cell-based therapy of neurodegenerative disorders. Acta Neurobiol Exp (Wars) (2015) 0.75